-+ 0.00%
-+ 0.00%
-+ 0.00%

According to the announcement of Prodrug Pharmaceuticals, Zhejiang Projutai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has received a notice from the US FDA, and its application for a simplified new drug for bricetan tablets has been approved. This drug is a tablet with specifications of 25 mg, 50 mg, and 100 mg. It is mainly used to treat partial seizures of epilepsy. The manufacturer is Zhejiang Pulo Kangyu Pharmaceutical Co., Ltd. In 2025, the sales volume of brinacetam tablets in the US market was approximately US$823 million. This approval indicates that the company is qualified to sell this product in the US market, which has a positive effect on the company's business development.

Zhitongcaijing·09/14/2026 08:09:05
Listen to the news
According to the announcement of Prodrug Pharmaceuticals, Zhejiang Projutai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has received a notice from the US FDA, and its application for a simplified new drug for bricetan tablets has been approved. This drug is a tablet with specifications of 25 mg, 50 mg, and 100 mg. It is mainly used to treat partial seizures of epilepsy. The manufacturer is Zhejiang Pulo Kangyu Pharmaceutical Co., Ltd. In 2025, the sales volume of brinacetam tablets in the US market was approximately US$823 million. This approval indicates that the company is qualified to sell this product in the US market, which has a positive effect on the company's business development.